Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma

Wael K Al-Delaimy, Amira Awadalla, Ahmed El-Assmy, Hassan Abol-Enein, Ahmed Shokeir, Wael K Al-Delaimy, Amira Awadalla, Ahmed El-Assmy, Hassan Abol-Enein, Ahmed Shokeir

Abstract

Background: Squamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matrix protein-22 (NMP22), telomerase activity, and CD44 were evaluated in urine samples of patients with bladder SCC.

Materials and methods: We conducted a case-control study comprised of 60 consecutive newly diagnosed bladder SCC patients diagnosed by cystoscopy and histopathological examination, and controls were 60 outpatients with benign urologic conditions and healthy clinic visitors. Urine samples collected from each subject underwent testing for NMP22, telomerase activity, and CD44. Descriptive and correlational statistical analysis of cases and controls were carried out and receiver operating characteristic curve analysis was used to determine optimal cut-off points for the three assays.

Results: Area under the curve was calculated at 0.96, 0.93, and 0.62 for NMP22, telomerase, and CD44, respectively. Urine levels of NMP22 and telomerase activity were significantly higher in the SCC group compared to controls (p < 0.001). Urine CD44 levels were not significantly higher in the SCC group compared to controls (p = 0.111). The overall sensitivity of NMP22, telomerase, and CD44 was 96.7%, 87%, and 45%, respectively, while the specificity was 85%, 88.6%, and 86.7%, respectively.

Conclusions: Urinary telomerase activity, followed by NMP22 urine levels, showed high diagnostic yield and could hold potential promise as urinary biomarkers for the diagnosis of bladder SCC.

Keywords: Bladder tumor; CD44; NMP22; Squamous cell carcinoma; Telomerase; Tumor markers.

Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Receiver operating characteristic curves for urinary CD44, NMP22, and telomerase, to detect squamous cell bladder cancer. NMP22 = nuclear matrix protein-22.

References

    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017;71(1):96–108.
    1. Shokeir AA. Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment. BJU Int 2004;93(2):216–220.
    1. Al-Husseini MJ Kunbaz A Saad AM, et al. . Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: A SEER-based analysis. BMC Cancer 2019;19(1):46.
    1. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: A review. Eur Urol 2003;44(6):672–681.
    1. Redondo-Gonzalez E de Castro LN Moreno-Sierra J, et al. . Bladder carcinoma data with clinical risk factors and molecular markers: A cluster analysis. Biomed Res Int 2015;2015:168682.
    1. Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol 2007;25(3):260–268.
    1. El-Sebaie M, Zaghloul M, Howard G, Mokhtar A. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management. Int J Clin Oncol 2005;10(1):20–25.
    1. World Health Organization (WHO). Schistosomiasis. Fact Sheet 2020. Available at: . Accessed August 8, 2020.
    1. Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 1999;12(1):97–111.
    1. Ibrahim AS, Khaled HM, Mikhail NH, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol 2014;2014:437971.
    1. Khaled H. Schistosomiasis and cancer in Egypt: Review. JAdv Res 2013;4(5):461–466.
    1. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000;77(1):41–51.
    1. Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: An update. World J Urol 2020;38(8):1895–1904.
    1. The National Cancer Institute. Available at: . Accessed August 8, 2020.
    1. Gopalakrishna A Longo TA Fantony JJ, et al. . The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. BMC Urol 2016;16(1):30.
    1. Konety BR. Molecular markers in bladder cancer: A critical appraisal. Urol Oncol 2006;24(4):326–337.
    1. Blick CG Nazir SA Mallett S, et al. . Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: Results for 778 patients from a hospital haematuria clinic. BJU Int 2012;110(1):84–94.
    1. Soria F Droller MJ Lotan Y, et al. . An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. WorldJUrol 2018;36(12):1981–1995.
    1. El-Kenawy Ael-M, El-Kott AF, Khalil AM. Prognostic value of p53 and MDM2 expression in bilharziasis–associated squamous cell carcinoma of the urinary bladder. Int J Biol Markers 2003;18(4):284–289.
    1. Youssef RF von Rundstedt FC Kapur P, et al. . Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma. J Urol 2015;193(2):451–456.
    1. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 1976;72:248–254.
    1. Kim NW Piatyszek MA Prowse KR, et al. . Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011–2015.
    1. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995;23(18):3794–3795.
    1. Lambert J, Lipkovich I. A macro for getting more out of your ROC curve (SAS global forum poster presentation); 2008. Available at: . Accessed August 8, 2020.
    1. Moonen PM, Kiemeney LA, Witjes JA. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol 2005;48(6):951–956.
    1. Cheng CW, Chueh SC, Chern HD. Diagnosis of bladder cancer using telomerase activity in voided urine. J Formos Med Assoc 2000;99(12):920–925.
    1. Eissa S Swellam M El-Mosallamy H, et al. . Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res 2000;23(5b):4347–4355.
    1. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161(2):388–394.
    1. Bravaccini S, Casadio V, Amadori D, Calistri D, Silvestrini R. The current role of telomerase in the diagnosis of bladder cancer. Indian J Urol 2009;25(1):40–46.
    1. Casadio V Bravaccini S Gunelli R, et al. . Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. Int J Biol Markers 2009;24(4):253–257.
    1. Mezzasoma L Antognelli C Del Buono C, et al. . Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. MC Urol 2010;10:17.
    1. Atsü N, Ekici S, Oge OO, Ergen A, Hasçelik G, Ozen H. False-positive results of the NMP22 test due to hematuria. J Urol 2002;167(2 Pt 1):555–558.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit